Enhanced radioimmunotherapeutic efficacy of a monoclonal antibody cocktail against SMMC-7721 human hepatocellular carcinoma

Abstract

The improved tumoricidal effect of the radioantibody mixture ("cocktail") has been reported recently for the treatment of colon tumor. In the present study, we demonstrated the enhanced radioimmunotherapeutic efficacy of a monoclonal antibody (MAb) cocktail against human hepatocellular carcinoma. Therapeutic efficacy was determined by measuring the change in tumor size over a period, determining the percentage of growth inhibition of each treatment at various times after radioantibody therapy.

Antibody production: Polyclonal-derived biotherapeutics

“…Several antibody cocktails have been developed in the hope of providing a cost-effective and safe replacement to human polyclonal antibodies and resolve some of the potential limitations of monoclonal antibody therapies. A number of these antibody cocktails have been evaluated using in vivo models, including human rabies virus-neutralizing monoclonal antibody cocktails [29] and radiolabelled monoclonal antibody (mAb) mixtures for the treatment of carcinoma [30]. Although a mAb 'cocktail' approach may confer many of the advantages of polyclonal-derived antibody products, there are major commercial and technical obstacles to overcome as a result of the requirement for large-scale cGMP manufacture [31,32].…”

Suppression of Human Hepatoma Growth in vivo by a Monoclonal Antibody Against a Mr 45,000 Protein

“…Promising antibodies are under investigation for both HCC prevention and treatment. Effective antibodies include 131 I conjugated anti-CD147 antibody fragment HAb18 F(ab ) 2 for HCC diagnosis and therapy that will soon reach market (5) and 131 I-labeled Hepama-I specific for the SMMC 7721 cell line which is now in clinical trial (6). Antibodies and antibody conjugates targeting HBV or HCV surface antigens (7,8) have been applied for HCC prevention and therapy (9,10).…”